MétaCan
Menu
Back to cohort
Record W2913756819 · doi:10.1016/j.bbmt.2020.05.001

Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

2020· article· en· W2913756819 on OpenAlexaff
Annie Im, Armin Rashidi, Tao Wang, Michael Hemmer, Margaret L. MacMillan, Joseph Pidala, Madan Jagasia, Steven Z. Pavletic, Navneet S. Majhail, Daniel J. Weisdorf, Hisham Abdel‐Azim, Vaibhav Agrawal, A. Samer Al‐Homsi, Mahmoud Aljurf, Medhat Askar, Jeffery J. Auletta, Asad Bashey, Amer Beitinjaneh, Vijaya Raj Bhatt, Michael Byrne, Jean‐Yves Cahn, Mitchell S. Cairo, Paul Castillo, Jan Černý, Saurabh Chhabra, Hannah Choe, Stefan O. Ciurea, Andrew Daly, Miguel Ángel Díaz, Nosha Farhadfar, Shahinaz M. Gadalla, Robert Peter Gale, Siddhartha Ganguly, Usama Gergis, Rabi Hanna, Peiman Hematti, Roger H. Herzig, Gerhard Hildebrandt, Deepesh Lad, Catherine Lee, Leslie Lehmann, Lazaros J. Lekakis, Rammurti T. Kamble, Mohamed A. Kharfan‐Dabaja, Pooja Khandelwal, Rodrigo Martino, Hemant S. Murthy, Taiga Nishihori, Tracey O’Brien, Richard F. Olsson, Sagar S. Patel, Miguel‐Angel Perales, Tim Prestidge, Muna Qayed, Rizwan Romee, Hélène Schoemans, Sachiko Seo, Akshay Sharma, Melhem Solh, Roger Strair, Takanori Teshima, Álvaro Urbano-Ispizúa, Marjolein van der Poel, Ravi Vij, John L. Wagner, Basem M. William, Baldeep Wirk, Jean A. Yared, Mukta Arora, Betty K. Hamilton

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2020
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsBaker Hughes (Canada)
FundersNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchTakeda OncologyHealth Resources and Services AdministrationDaiichi-SankyoSwedish Orphan BiovitrumOmeros CorporationJanssen Scientific AffairsMundipharma EDOAstellas PharmaAdaptive Biotechnologiesbluebird bioMedical College of WisconsinChimerixMedacJazz PharmaceuticalsNational Institutes of HealthRegeneron PharmaceuticalsKaryopharm TherapeuticsJanssen PharmaceuticalsMemorial Sloan-Kettering Cancer CenterSanofi GenzymePatient-Centered Outcomes Research InstituteJanssen BiotechHistoGeneticsCelgeneAtara BiotherapeuticsActinium PharmaceuticalsDaiichi Sankyo EuropeNational Cancer InstituteGilead SciencesSanofiSpectrum PharmaceuticalsBiomedical Advanced Research and Development AuthorityAmgenNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationIncytePfizerCSL BehringBristol-Myers SquibbGlaxoSmithKlineAstellas Pharma US
KeywordsMedicineHazard ratioInternal medicineGraft-versus-host diseaseMyeloid leukemiaTransplantationCyclophosphamideGastroenterologyHematopoietic stem cell transplantationIncidence (geometry)Bone marrowLeukemiaImmunologySurgeryConfidence intervalChemotherapy

Abstract

fetched live from OpenAlex

Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus <29 years) was significantly associated with higher rates of grade 2 to 4 acute GVHD (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.11 to 2.12; P = .01). In contrast, PB compared to BM as a stem cell source was a significant risk factor for the development of chronic GVHD (HR, 1.70; 95% CI, 1.11 to 2.62; P = .01) in the RIC setting. There were no differences in relapse or overall survival between groups. Donor age and graft source are risk factors for acute and chronic GVHD, respectively, after PTCy-based haplo-HCT. Our results indicate that in RIC haplo-HCT, the risk of chronic GVHD is higher with PB stem cells, without any difference in relapse or overall survival.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.037
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.262
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations64
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207